{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:23:49Z","timestamp":1760300629053},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer Yakuhin, Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003The efficacy and safety of rivaroxaban have been demonstrated in phase 3 trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep vein thrombosis [DVT]). Data regarding rivaroxaban treatment of VTE in routine Japanese clinical practice remain limited.<\/jats:p><jats:p>\n          Objectives\u2003XASSENT will evaluate rivaroxaban treatment of VTE in real-world Japanese clinical practice. We report the study design and baseline patient characteristics.<\/jats:p><jats:p>\n          Methods\u2003XASSENT (NCT02558465) is an open-label, prospective observational, post-marketing surveillance cohort study in patients receiving rivaroxaban treatment for VTE. Enrolment took place between November 2015 and March 2018. XASSENT will follow patients for up to 2 years. Primary outcome variables: major bleeding and symptomatic recurrent VTE. Statistical analyses are exploratory and descriptive.<\/jats:p><jats:p>\n          Results\u2003Baseline patient characteristics at June 2020 (n\u2009=\u20092,299) are presented (58.2% female; mean age 66.7 years; mean weight 60.9\u2009kg). The population encompasses patients with wide-ranging characteristics including older age, low weight, and renal dysfunction. Most participants (67.6%) had a history of VTE risk factors at baseline. Half of the population (50.4%) had DVT only; 41.4% had DVT with PE; 8.2% had PE only. Overall, 68.4% were inpatients and 77.1% had symptomatic VTE. Rivaroxaban was prescribed for initial treatment in 84.6% of patients and maintenance treatment in 15.4%. Most were prescribed the approved dose of rivaroxaban for initial (30\u2009mg daily; 84.4%) or maintenance (15\u2009mg daily; 81.9%) treatment of VTE in Japan. The most common reason for selecting non-recommended dose was \u2018elderly\u2019.<\/jats:p><jats:p>\n          Conclusions\u2003Results from XASSENT will complement phase 3 trial data and inform clinical practice.<\/jats:p>","DOI":"10.1055\/a-1664-1164","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T23:03:44Z","timestamp":1633647824000},"page":"e521-e532","source":"Crossref","is-referenced-by-count":2,"title":["Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)"],"prefix":"10.1055","volume":"05","clinical-trial-number":[{"clinical-trial-number":"nct02558465","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ikuo","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Suita Tokushukai Hospital, Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Police Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kawasugi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Hamamatsu Medical Center, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Nakamura Medical Clinic, Kuwana, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Namba Clinic, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kuwana City Medical Center, Kuwana, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Tajima","sequence":"additional","affiliation":[{"name":"Medical Affairs Cardiovascular and Nephrology, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghun","family":"Iwashiro","sequence":"additional","affiliation":[{"name":"Medical Affairs Cardiovascular and Nephrology, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okayama","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Monitoring and Governance, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sunaya","sequence":"additional","affiliation":[{"name":"Statistics and Data Insights, Data Sciences and Analytics, Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Hirano","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Monitoring and Governance, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Hayasaki","sequence":"additional","affiliation":[{"name":"Medical Affairs Cardiovascular and Nephrology, Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jjcc.2015.03.012","article-title":"Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy","volume":"66","author":"M Nakamura","year":"2015","journal-title":"J Cardiol"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"e014582","DOI":"10.1161\/JAHA.119.014582","article-title":"Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROAD-DPC","volume":"9","author":"Y Yamashita","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12959-015-0035-3","article-title":"Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program","volume":"13","author":"N Yamada","year":"2015","journal-title":"Thromb J"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"H R B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"M H Prins","year":"2013","journal-title":"Thromb J"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"W Ageno","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2019.02.010","article-title":"XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America","volume":"176","author":"R Kreutz","year":"2019","journal-title":"Thromb Res"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"T Tanigawa","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study \u2013","volume":"76","author":"M Hori","year":"2012","journal-title":"Circ J"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1253\/circj.CJ-88-0010","article-title":"Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009)","volume":"75","author":"JCS Joint Working Group","year":"2011","journal-title":"Circ J"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1253\/circj.CJ-17-0579","article-title":"Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011","volume":"82","author":"S Ota","year":"2018","journal-title":"Circ J"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1253\/circj.CJ-20-0636","article-title":"A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study)","volume":"84","author":"Y Okumura","year":"2020","journal-title":"Circ J"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"M H Prins","year":"2014","journal-title":"Lancet Haematol"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1253\/circj.CJ-13-0886","article-title":"Current venous thromboembolism management and outcomes in Japan","volume":"78","author":"M Nakamura","year":"2014","journal-title":"Circ J"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry","volume":"82","author":"Y Yamashita","year":"2018","journal-title":"Circ J"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1253\/circrep.CR-19-0127","article-title":"Safety and Effectiveness of Edoxaban in Japanese Venous Thromboembolism Patients - Final Analysis of One-Year Follow-up Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan)","volume":"2","author":"M Nakamura","year":"2020","journal-title":"Circ Rep"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1664-1164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:14:10Z","timestamp":1638490450000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1664-1164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":19,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1664-1164","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}